Award & Investment Overview
Virginia Commonwealth University (VCU) TechTransfer and Ventures has announced the latest recipients of its Commercialization Fund, selecting six faculty-led research projects to receive commercialization funding that will accelerate technologies toward licensing, startup formation, regulatory development, and market readiness.
Administered through the Office of the Vice President for Research and Innovation, the Commercialization Fund provides twice-yearly awards that help researchers validate technologies, reduce commercialization risk, and prepare innovations for follow-on investment and industry engagement. Since launching in 2015, the program has supported more than 100 faculty researchers with over $4.1 million in funding, helping leverage an additional $41.4 million in external funding from federal agencies, investors, licensing partners, and state organizations.
The latest awardees span biosensors, medical imaging, pulmonary drug delivery, autonomous systems, radiation oncology, and metabolic disease therapeutics, demonstrating the breadth of VCU’s commercialization pipeline.
Approach & Ecosystem Context
The VCU Commercialization Fund exemplifies how university commercialization programs support researchers during the critical transition between laboratory validation and external commercialization.
Rather than funding basic research, the program enables investigators to complete prototype development, generate validation data, engage potential customers, prepare regulatory strategies, and strengthen licensing opportunities before seeking larger investments or strategic partnerships.
From a Mind the GAP perspective, institutional commercialization funds play a central role in reducing technical, regulatory, and market risk. By supporting milestone-driven development activities, these programs help researchers generate the evidence needed to attract licensing partners, investors, federal translational funding, and startup capital.
VCU’s long-term commercialization outcomes demonstrate the value of sustained institutional investment in proof-of-concept and technology maturation funding, with follow-on funding exceeding ten times the university’s direct commercialization investment.
Innovation & Technology
The latest Commercialization Fund cohort includes six technologies addressing significant healthcare and engineering challenges.
CortiSense is advancing a rapid point-of-care cortisol biosensor capable of delivering laboratory-quality results in less than 10 minutes.
NIROS is developing a near-infrared optical imaging system for real-time assessment of tissue oxygenation without contrast agents.
A novel dry powder drug delivery platform combines therapeutics with lung surfactants to improve treatment of respiratory diseases.
A geometry-aware uncertainty calibration algorithm improves autonomous tracking for cooperative unmanned aerial vehicle systems.
A portable, foldable water tank system simplifies commissioning and quality assurance for radiation therapy equipment.
A first-in-class endogenous epigenetic therapeutic is being developed to treat metabolic dysfunction-associated steatotic liver disease (MASLD).
Potential Market Uses and Applications
CortiSense
Potential Clinical Applications
- Point-of-care cortisol testing
- Emergency medicine
- Endocrinology
- Mental health diagnostics
- Stress biomarker monitoring
NIROS
Potential Clinical Applications
- Tissue viability assessment
- Peripheral vascular disease
- Diabetic wound care
- Surgical planning
- Critical limb ischemia
Drug-Surfactant Combination Aerosol Platform
Potential Clinical Applications
- Acute respiratory distress syndrome
- Severe pneumonia
- Inhaled therapeutics
- Pulmonary drug delivery
- Vaccine delivery
Geometry-Aware Uncertainty Calibration for Cooperative Multi-Unmanned Aerial Vehicles
Potential Aerospace & Defense Applications
- Autonomous drone operations
- Defense systems
- Multi-UAV coordination
- Autonomous navigation
- Robotics
Portable and Foldable Water Tank System
Potential Clinical Applications
- Radiation oncology
- Medical physics
- Cancer treatment quality assurance
- Medical device services
Cholestenoic Acid (CA) for MASLD
Potential Therapeutic Applications
- Metabolic dysfunction-associated steatotic liver disease
- Liver disease therapeutics
- Epigenetic medicine
- Drug development
Related Topics
university commercialization, commercialization fund, proof-of-concept funding, GAP programs, technology transfer, translational research, medical devices, digital health, therapeutics, university innovation
About innovosource
innovosource tracks GAP programs, including proof-of-concept programs, startup accelerators, translational research initiatives, university venture funds, and commercialization ecosystems that help move university innovations from research to market.
Our coverage is informed by the Mind the GAP Initiative and the GAP COA consortium activity, providing practical insights into the evolving commercialization landscape.
Learn more: https://www.innovosource.com/mind-the-gap/
